Pisa syndrome in a patient with pathologically confirmed Parkinson's disease

2016 ◽  
Vol 42 (7) ◽  
pp. 654-658 ◽  
Author(s):  
Paolo Solla ◽  
Oriol Grau-Rivera ◽  
Ellen Gelpi ◽  
Francesco Marrosu ◽  
Maria José Martí
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Pisa Syndrome

scholarly journals Use of Botulinum Neurotoxin in Parkinson’s Disease: A Critical Appraisal

Toxins ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 87
Author(s):  
Wolfgang H. Jost
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Botulinum Neurotoxin ◽  
Critical Appraisal ◽  
Freezing Of Gait ◽  
Sufficient Data ◽  
Pisa Syndrome ◽  
Focal Hyperhidrosis ◽  
Detrusor Hyperactivity ◽  
Important Indication

For well over 30 years, the botulinum neurotoxin (BoNT) has been used for a large number of indications, some of which however have not been licensed. Admittedly, approval varies in many countries and this permits a large spectrum for evaluation. Thus, BoNT is used for patients with Parkinson’s disease (PD) and other Parkinson’s syndromes (PS) in varying degrees of frequency. We have to distinguish between (1) indications that are either approved or (2) those not approved, (3) indications that might be a result of PS and (4) finally those which appear independent of PS. The most important indication for BoNT in PS patients is probably sialorrhea, for which approval has been granted in the majority of countries. Cervical dystonia is a frequent symptom in PS, with anterocollis as a specific entity. A further indication is blepharospasm in the different forms, especially the inhibition of eyelid opening in atypical PS. The use of BoNT in cases of camptocormia, the Pisa syndrome and neck rigidity is still a matter of debate. In dystonia of the extremities BoNT can be recommended, especially in dystonia of the feet. One well-known indication, for which however sufficient data are still lacking, involves treating tremor with BoNT. As to autonomic symptoms: Focal hyperhidrosis and detrusor hyperactivity can be mentioned, in this last case BoNT has already been approved. A number of further but rare indications such as freezing-of-gait, dyskinesia, and dysphagia will be discussed and evaluated.

P6.18 Pisa Syndrome in Parkinson's disease: EMG features disclose two different underlying pathophysiological mechanisms

2011 ◽  
Vol 122 ◽  
pp. S88
Author(s):  
A. Fasano ◽  
A. Di Matteo ◽  
G. Squintani ◽  
L. Ricciardi ◽  
T. Bovi ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Pathophysiological Mechanisms ◽  
Pisa Syndrome

Pisa syndrome without neuroleptic exposure in a patient with Parkinson's disease: Case report

2006 ◽  
Vol 21 (2) ◽  
pp. 270-273 ◽  
Author(s):  
Mattia Gambarin ◽  
Angelo Antonini ◽  
Giuseppe Moretto ◽  
Paolo Bovi ◽  
Silvia Romito ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Case Report ◽  
Pisa Syndrome ◽  
Disease Case

scholarly journals Pisa syndrome after rasagiline therapy in a patient with Parkinson’s disease

2015 ◽  
Vol 36 (12) ◽  
pp. 2305-2305 ◽  
Author(s):  
F. Valentino ◽  
G. Cosentino ◽  
B. Fierro ◽  
S. Realmuto ◽  
S. Mastrilli ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Pisa Syndrome

scholarly journals Pisa Syndrome in Parkinson's Disease Is Associated With Specific Cognitive Alterations

2019 ◽  
Vol 10 ◽  
Author(s):  
Carlo Alberto Artusi ◽  
Elisa Montanaro ◽  
Sara Tuttobene ◽  
Alberto Romagnolo ◽  
Maurizio Zibetti ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Pisa Syndrome ◽  
Cognitive Alterations
Sign in / Sign up

Export Citation Format

Share Document